FY2030 Earnings Forecast for Savara Issued By HC Wainwright

Key Points

• HC Wainwright’s A. Fein projects FY2030 EPS of $0.91 for Savara and maintains a Buy rating with a $10 target, versus the current consensus full-year EPS of ($0.45).
• Analyst sentiment is mixed but leans positive—one Strong Buy, six Buy, one Hold and one Sell—yielding an average rating of Moderate Buy and an average target of $8.86.
• Savara (market cap ~$1.14B) is a clinical-stage biotech whose lead candidate, Molgradex, is under regulatory review for autoimmune pulmonary alveolar proteinosis, and institutional investors own about 87.9% of the stock.

Savara Inc. (NASDAQ:SVRA - Free Report) - HC Wainwright issued their FY2030 earnings per share estimates for shares of Savara in a report released on Monday, March 9th. HC Wainwright analyst A. Fein forecasts that the company will earn $0.91 per share for the year. HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for Savara's current full-year earnings is ($0.45) per share.

SVRA has been the topic of a number of other research reports. Wells Fargo & Company lifted their price target on shares of Savara from $7.00 to $9.00 and gave the company an "overweight" rating in a research report on Thursday, December 18th. Wall Street Zen raised shares of Savara from a "sell" rating to a "hold" rating in a report on Saturday, November 15th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Savara in a research note on Thursday, January 22nd. Citizens Jmp dropped their target price on shares of Savara from $11.00 to $10.00 and set a "market outperform" rating on the stock in a report on Thursday, November 13th. Finally, Oppenheimer set a $10.00 target price on shares of Savara in a research report on Tuesday, December 23rd. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $8.86.

Savara Stock Up 3.3%

SVRA opened at $5.61 on Wednesday. The firm has a market cap of $1.14 billion, a P/E ratio of -10.58 and a beta of 0.31. The company has a debt-to-equity ratio of 0.32, a quick ratio of 7.65 and a current ratio of 7.65. The business has a 50 day moving average price of $5.70 and a 200 day moving average price of $4.92. Savara has a twelve month low of $1.89 and a twelve month high of $7.01.

Institutional Investors Weigh In On Savara

Hedge funds have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd grew its stake in shares of Savara by 1,887.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 39,649 shares of the company's stock worth $239,000 after acquiring an additional 37,654 shares during the last quarter. Seven Fleet Capital Management LP acquired a new position in Savara during the 4th quarter valued at $378,000. Virtu Financial LLC acquired a new position in Savara during the 4th quarter valued at $396,000. Invesco Ltd. boosted its holdings in Savara by 302.1% in the 4th quarter. Invesco Ltd. now owns 688,595 shares of the company's stock valued at $4,152,000 after purchasing an additional 517,329 shares during the period. Finally, KVP Capital Advisors LP acquired a new stake in Savara in the 4th quarter worth $3,650,000. 87.93% of the stock is owned by institutional investors.

About Savara

Savara Inc NASDAQ: SVRA is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company's lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.